by admin | 16 October 2023 | News
Numeric improvements were seen across key multiple sclerosis measures, including the Modified Fatigue Impact Scale, Expanded Disability Status Scale, Timed 25-Foot Walk test, Pyramidal Scores and NeuroQoL™ Fatigue scores. Data was presented at ECTRIMS (39th Congress... by admin | 13 October 2023 | News
Five out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being observed)Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal... by admin | 26 September 2023 | News
NEW YORK, September 26, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of delivery, today announced that it held an Investigator’s Meeting with...
by admin | 12 September 2023 | Media
Sep. 12, 2023 By Mar de Miguel Alzheimer’s disease (AD) has a new candidate for its treatment. Nasal anti-CD3 monoclonal antibody (MAb) reduced microglia activation in the brain of mice without its effect being dependent on the β-amyloid (Aβ) deposits characteristic... by admin | 8 September 2023 | News
NEW YORK, September 8, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company will virtually present... by admin | 6 September 2023 | News
The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)” FDA has cleared the IND for intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for human study... by admin | 23 August 2023 | News
Leadership Addition Strengthens Company’s Commitment to Advancing Innovative Therapies NEW YORK, August 23, 2023 — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation... by admin | 23 August 2023 | News
NEW YORK, August 23 2023 — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced an oral presentation of “Nasal... by admin | 17 August 2023 | News
NEW YORK, August 17, 2023 — Tiziana Life Sciences Ltd. (Nasdaq:TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Dr. Howard L. Weiner, a thought...
by admin | 16 August 2023 | Media
FDA Clears IND to Test Intranasal Foralumab in Alzheimer Disease Aug 15, 2023 Isabella Ciccone, MPH Foralumab, a therapy designed to bind to T cell receptor, is about to be assessed in phase 2 trials of patients with non-active secondary progressive multiple sclerosis... by admin | 15 August 2023 | News
Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibody Trial to be overseen by Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System NEW YORK, August 15,... by admin | 9 August 2023 | News
NEW YORK, September 8, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company will virtually present... by admin | 21 July 2023 | News
New York, July 21, 2023 – Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today disclosed the receipt of a notice...
by admin | 15 June 2023 | Media
Through an expanded access program, new announced data from a small cohort of patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with foralumab (Tiziana Life Sciences), an investigational anti-CD3 monoclonal antibody, showed reduction... by admin | 13 June 2023 | News
NEW YORK, June 13, 2023 — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce the appointment of Matthew... by admin | 8 June 2023 | Media
Reductions in microglial activation have been observed in the brains of five of six patients with nonactive secondary progressive multiple sclerosis (SPMS) who received treatment with Tiziana Life Science’s foralumab nasal spray. Microglia, resident immune cells in... by admin | 5 June 2023 | News
Results confirm positive signal previously reported in the first two Expanded Access patients who both subsequently demonstrated clinical improvements Phase 2a trial in na-SPMS on track to begin in Q3 2023 KOL webinar with Howard L. Weiner, M.D., Chairman of... by admin | 25 May 2023 | News
NEW YORK, May 25, 2023 — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it will host a virtual KOL event to... by admin | 23 May 2023 | News
NEW YORK, May 23, 2023 — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that they are now participating on the... by admin | 17 May 2023 | News
NEW YORK, May 17, 2023 — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Medical Officer is... by admin | 27 April 2023 | News
There are no effective treatments for intracerebral hemorrhage (ICH), which has a 30% to 40% mortality rate Intranasal anti-CD3 mAb treatment showed a reduction in Intracerebral Hemorrhage injury severity Intranasal foralumab could represent a novel therapeutic... by admin | 26 April 2023 | News
NEW YORK, April 26, 2023 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced financial results for the twelve months... by admin | 24 April 2023 | News
NEW YORK, April 24, 2023 — Tiziana Life Sciences Ltd.. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that it has received a notification...
